Subscribe to Search results

Dr John Cash established the SNBTS Coagulation Factor Study Group.

Published on:

PFC produced 11 pilot batches of "ZHT" and tested their clinical validity in late 1983.

Published on:

PFC and SNBTS prioritised dry heat treatment over pasteurisation after the the data presented at Groningen showed that it could inactivate HTLV-3.

Published on:

PFC heat treated its existing 12-month stock of Factor 8 batches manufactured as early as October 1983.

Published on:

PFC heat treated products for 24 hours (extended from 2 hours).

Published on:

PFC experienced issues with the freeze drying process in relation to the production of Z8.

Published on:

Clinical trials of Z8 were delayed due to a question about compensation to patients who might be harmed during the trials raised by Prof Ludlam, supported by all of Scotland's haemophilia doctors.

Published on:

Dr Peter Foster was head of the R&D Department of the SNBTS PFC.

Published on:

Dr Peter Foster was a biochemist at PFC.

Published on:

A H Woodhead wrote to all Blood Transfusion Service directors about a batch of Factorate recalled by Armour Pharmaceuticals.

Published on:

The Committee on Safety of Medicines reviewed Dr Peter Jones' letter regarding AIDS and the heat treatment of clotting factor and advised that there was insufficient evidence for action to be taken on any specific product.

Published on:

Dr Jones apologised to the DHSS for making public his statement about heat-treated Factor 8 being unsafe.

Published on:

The CBLA agreed to finance the trial of 8CRV.

Published on:

Dr Brian Colvin thought that it would be more problematic if the heat-treated commercial products turned out to be unsafe from HIV.

Published on:

The Krever Inquiry found that Armour should have informed the Canadian Bureau of Biologics about Dr Prince's findings, but chose not to.

Published on:

Contrary to the findings of the Krever Inquiry, Justice Benotto, in a subsequent Canadian criminal case in 2007, found that it would have been unreasonable and irresponsible for Armour to have thrust Prince's studies into the community in a time of great uncertainty.

Published on:

The Northern Regional Health Authority's position on funding additional cost was yet to be declared.

Published on:

Armour Pharmaceutical Company Limited in the UK was incorporated in 1959. It had several changes in name and parent company and was dissolved in 2010.

Published on:

From mid March 1985 Cutter had taken the strategic decision to stop selling unheated stock to UK centres.

Published on:

An internal report of Cutter speaking of the UK sales position recorded that a small "short dated batch" of non-heat-treated concentrate was sold during the previous month.

Published on: